Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA) − PRODIGE 38: study protocol for a randomized controlled multicenter phase II/III study

Combination of cisplatine and Gemcitabine (CisGem) is the reference 1 st line Chemotherapy in patients with advanced biliary cancer. FOLFIRINOX demonstrated an overall survival superiority when compared to gemcitabine in 1 st line for patients with metastatic pancreatic adenocarcinoma. Because of similarities between pancreatic and biliary cancers, we proposed a randomized trial comparing mFOLFIRINOX and CisGEm.

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2DOQWJT
via IFTTT